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Alternatives for developing chronic exposure limits for noncancer effects of trichloroethylene (TCE)
were evaluated. These alternatives were organized within a framework for dose-response
assessment-exposure:dosimetry (pharmacokinetics):mode of action (pharmacodynamics):
response. This framework provides a consistent structure within which to make scientific judgments
about available information, its interpretation, and use. These judgments occur in the selection of
critical studies, internal dose metrics, pharmacokinetic models, approaches for interspecies
extrapolation of pharmacodynamics, and uncertainty factors. Potentially limiting end points included
developmental eye malformations, liver effects, immunotoxicity, and kidney toxicity from oral
exposure and neurological, liver, and kidney effects by inhalation. Each end point was evaluated
quantitatively using several methods. Default analyses used the traditional no-observed adverse
effect level divided by uncertainty factors and the benchmark dose divided by uncertainty factors
methods. Subsequently, mode-of-action and pharmacokinetic information were incorporated. Internal
dose metrics were estimated using a physiologically based pharmacokinetic (PBPK) model for TCE
and its major metabolites. This approach was notably useful with neurological and kidney toxicities.
The human PBPK model provided estimates of human exposure doses for the internal dose metrics.
Pharmacodynamic data ordefault assumptions were used for interspecies extrapolation. For liver and
neurological effects, humans appear no more sensitive than rodents when internal dose metrics
were considered. Therefore, the interspecies uncertainty factor was reduced, illustrating that
uncertainty factors are a semiquantitative approach fitting into the organizational framework.
Incorporation of pharmacokinetics and pharmacodynamics can result in values that differ significantly
from those obtained with the default methods. Key words: benchmark dose, chloral, developmental
toxicity, dose-response assessment, kidney toxicity, liver toxicity, neurotoxicity, PBPK modeling,
trichloroacetate, trichloroethylene. - Environ Health Perspect 108(suppl 2):323-334 (2000).
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The literature regarding noncancer effects due
to trichloroethylene (TCE) exposure is exten-
sive (reviewed in 1-5). Studies ofexposed
humans and experimental animals are avail-
able reporting a wide range ofeffects includ-
ing biochemical, cellular, and target-organ
alterations. A large number of organs and
organ systems have been reported to be tar-
gets at some dose in at least one study,
including most prominently the nervous sys-
tem, liver, and kidney. Due to the breadth of
this database, some of the most significant
challenges for evaluating options for non-
cancer risk assessment for TCE are the selec-
tion and interpretation ofpotential critical
studies. This challenge increases as efforts are
made to incorporate approaches for biologi-
cally based dose-response approaches because
mode-of-action and dosimetry information
are needed to analyze each end point.
Many studies ofexposed humans have
been published including epidemiological
studies ofworkers and the general population,
controlled experimental exposures, and med-
ical case studies ofworkers, overdose cases,
and others. There is a substantial literature for
acute effects in humans due to the use ofTCE
as an anesthetic and controlled human experi-
ments to studypotential neurological effects at
occupational exposure limits. In contrast,
efforts to determine potential chronic effects
of exposure have confronted the problems
that are typically associated with epidemiolog-
ical studies including exposure to mixtures,
difficulty demonstrating cause and effect, and
limited characterization ofexposure. There do
not appear to be human studies that would be
considered adequate for developing reference
doses (RfDs) and reference concentrations
(RfCs), subsequently referred to as toxicity
values, but human data playan important role
for cross-species comparisons of dose and
toxic effects.
Experimental studies generally used mice
and rats. Dosing regimens ranged from single
doses to lifetime oral or inhalation exposures.
While these studies generally involve well-
characterized exposures, their use for risk
assessment is critically dependent upon inter-
pretation ofthe toxicological significance ofthe
effects and interspecies extrapolations. Several
factors increase the difficulty ofinterpreting
study findings with TCE. Other than neuro-
logical and kidney toxicity, effects are rarely
observed in multiple species. Few studies are
done under good laboratory practices guide-
lines. Few end points in tissues not associated
with cancers have been studied in multiple
experiments orbymultiplelaboratories. Studies
report apparently contradictory results in sev-
eral areas (e.g., developmental toxicity), but the
exposure routes, methods, animal strains, or
other factors vary, which may explain the
variableresults.
The relationship between the doses used
for cancer and noncancer end points in the
animal studies with TCE is worth noting.
Chronic effects, particularly carcinogenicity,
are often thought to occur at lower concen-
trations than effects arising from shorter
exposures (except for developmental effects).
For TCE, all oral lifetime studies have used
relatively high doses: 500-1,000 mg/kg/day
for rats and 1,000-2,000 mg/kg/day for mice
in oil gavage studies. Inhalation studies have
covered a wider range ofdoses, 50-600 ppm.
These relativelyhigh exposure doses and con-
centrations have been used because they gen-
erally have been well tolerated by the animals,
although in some cases the maximum toler-
ated dose was exceeded. Similar and lower
doses have been used in studies of noncancer
end points in efforts to study dose-response
relationships.
A consistent framework has been evolv-
ing for analyzing dose-response information
that reflects relevant biological processes
(6,7). Depending on the availability ofinfor-
mation, different methods can be used
within the overall exposure-dosimetry mode-
of-action response framework (Figure 1). All
dose-response assessment methods begin
with the identification of a toxic effect and
then estimate acceptable exposure levels pro-
tective ofhuman health (7-10). The default
approach, in the absence ofinformation,
identifies a no-observed adverse effect level
(NOAEL) or lowest-observed effect level
(LOAEL) and then makes assumptions about
mode ofaction and dosimetry embodied in
standard uncertainty factors and adjustments
to continuous or daily exposure (11-14). An
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Figure 1. Framework for dose-response assessment. (A) Organization of biological information used in
dose-response assessment. (B) Options for dose-response assessment methods. While biological processes flow
from exposure to response, dose-response assessment begins with the response and works backward. The preferred
method uses quantitative pharmacokinetic and pharmacodynamic models to incorporate scientific data in a biologi-
cally based dose-response assessment. A more limited approach uses qualitative mode-of-action data to guide
quantitative pharmacokinetic modeling and needed extrapolations. The low information approach relates exposure
and response data using default assumptions.
alternative to the NOAEL is the benchmark
dose (BMD), a dose associated with a speci-
fied risk ofresponse determined using statisti-
cal curve fitting to dose-response data
(15-18). Additional scientific information
can be incorporated in dose-response analyses
by using a combination ofqualitative mode-
of-action information with quantitative phar-
macokinetic analysis (6,19,20). This
approach has begun to be incorporated into
noncancer dose-response assessment in the
RfC process (11). Use of mode-of-action
information helps to inform the pharmacoki-
netic analysis (i.e., selection ofan appropriate
dose metric) and the extrapolations accom-
plished with uncertainty factors (e.g., extrap-
olation ofless-than-chronic data or between
species). Opportunities to use these
approaches were evaluated here for noncancer
effects ofTCE. A more complete biologically
based dose-response assessment would use
quantitative descriptions of the mode of
action (i.e., pharmacodynamics) and dosime-
try (i.e., pharmacokinetics) in animals and
humans. Without relevant pharmacodynamic
models, this approach is not feasible for any
noncancer effects arising from exposure
to TCE.
The focus ofthe remainder ofthis article
will be a briefreview ofthe toxicity database
for TCE, evaluation ofoptions for the selec-
tion ofpotential critical studies upon which
to base dose-response values, and compar-
isons ofthe alternative methods for develop-
ing toxicity values. An extended version of
this analysis provides additional details and
quantitative alternatives (21).
Identification of Potential
Critical Studies
Selection ofpotential critical studies is aided
by well-designed studies using multiple doses
(11). Unfortunately, many studies with
TCE use only one or two doses, and data are
often unavailable at other doses. When only
high-dose data are reported, the studies are
relatively easy to exclude from further consid-
eration as potential critical studies because it is
clear that other studies report effects at lower
doses; these studies may then be considered
further as supporting data. When the exposure
doses used are relatively low, there is no simi-
larly easy criterion for including or excluding
the study. Rather, these decisions require con-
sideration ofthe strengths and weaknesses of
the overall database for the effect and the sci-
entific design and implementation of the
study. The following section describes the
general state ofthe database for end points
from which potential critical studies might be
selected with a particular focus on the
potential critical studies.
MethodsforSelectionofCriticalStudies
This article attempts to present the full range
ofoptions but ultimately also reflects the best
professionaljudgments ofits authors ofwhere
to focus their efforts. Therefore, an attempt
has been made to document thechioices made
so that, while others may agree or disagree,
the fact that those choices were made is
explicit and the reasoning is presented.
Potential critical studies were identified
in several ways. Existing literature reviews
were used extensively (3,4), particularly the
ToxicologicalProfilefor Trichloroethylene (1),
which includes reporting of the doses used
and lists key studies for a wide range of
effects. An analysis oforal toxicity studies
had been prepared previously with a similar
focus on risk assessment options (2).
Computerized searching ofMEDLINE and
TOXLINE (National Library ofMedicine,
Bethesda, MD) identified newer literature.
Based on these sources, original literaturewas
obtained for review to determine its suita-
bility as the basis for developing noncancer
dose-response values.
Selection ofthecritical studycannotsimply
be based on the doses used in the study
because different choices in methods (e.g.,
NOAEL vs BMD) and uncertainty factors
can alter which study results in the lowest
dose-response value. The choice was made to
evaluate the toxicological significance of
studies prior to calculating the dose-response
values rather than taking every study through
the quantitative analysis.
SelectionofOralStudies
End points evaluated in studies using oral
exposure to TCE include neurotoxicity (and
developmental neurotoxicity), immunotoxic-
ity, reproductive toxicity, developmental mal-
formations, kidney toxicity, and liver toxicity.
Studies selected for further evaluation are
summarized in Table 1.
Lifetime studies with TCE have predomi-
nantly focused on cancer and used high doses
(. 500 mg/kg/day for rats and 2 1,000
mg/kg/day for mice) (22-24). These studies
consistently report noncancer kidney toxicity
in both species. A 6-month drinking water
study using a wider range ofdoses (20-700
mg/kg/day) reported small changes in gross
pathology, hematology, and alteration in
immunological end points (25,26).
TCE is known to be neurotoxic in
humans and animals, particularly at high oral
and inhalation doses. The human studies
include medical reports from use ofTCE as
an inhalation anesthetic and inadvertent or
intentional acute consumption oflarge quan-
tities ofTCE. Epidemiological studies have
been performed on workers exposed by
inhalation and populations drinking TCE-
contaminated water (1). Studies have
reported changes in varied measures ofneuro-
physiology such as blink reflex (indicating
changes in the functioning ofcranial nerves)
and neuropsychology (27,28). These human
studies were not considered satisfactory for
developing toxicityvalues, although they may
be considered supportive data.
Neurobehavioral effects are readily
observed in rodents following acute, sub-
chronic, or chronic dosing with 500
mg/kg/day or more (24,29-32). Studies of
alterations in behavior and nervous system tis-
sue histopathology or biochemistry following
developmental exposure present mixed results
(33-35). Options for potential critical studies
are limited (32,36). One study exposed
neonatal mice for 6 days and reported changes
in one ofthree neurobehavioral measures at
one oftwo later time periods (36); this study
was considered too limited for quantitative
analysis but is supportive of similar
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LOAELs/NOAELs for other effects. The best
of the oral neurobehavioral studies exposed
adult rats to TCE for only 14 days and its
NOAEL (150 mg/kg/day) is relatively high
compared to others, so it was not considered
further (32).
Limited data from human and animal
studies are available on immunological effects
ofTCE (1). A few potentially immunologi-
cally related effects have been reported in
humans, although the associations with TCE
are speculative (4). Immunotoxicity was stud-
ied in outbred CD-1 mice exposed for up to 6
months to TCE in drinking water with 1%
emulphor (approximately 20, 200, 400, and
700 mg/kg/day) (26). Ten different measures
ofhumoral and cell-mediated immune func-
tion were measured in males and females at 4
and 6 months. Overall, effects were more fre-
quently observed in females, suggesting they
are more sensitive, but the difference is
unlikely to be pharmacokinetic because males
metabolize more TCE. The positive findings
for the antibody-forming (or plaque-forming)
cells and the delayed hypersensitivity assay are
notable in light ofrecent analyses showing the
antibody-forming assay alone and the two
assays together are highly predictive of
immunotoxicity (37,38). The authors con-
clude that in females, measures ofantibody-
dependent immune function were affected at
the two highest doses, while measures ofcell
immunity were affected at all four doses, but
males were relatively unaffected. A similar
study with chloral hydrate reported some
effects in females, suggesting metabolites of
TCE may be the active agents (39). The
Sanders et al. study was evaluated further as a
potential critical study (26).
No adverse reproductive effects have been
reported for humans exposed orally to TCE
(1). Several animal reproductive studies have
been reported in the literature including two-
generation studies with mice and rats using
microencapsulated TCE in feed (33,40-44).
These studies have generally been negative for
a wide range of reproductive end points
except at very high doses (approximately
1,000 mg/kg/day). In some cases, there are
inconsistent results (e.g., for sperm malforma-
tion), although these may reflect differences
in dosing, species, or strains ofanimals. Due
to the limited positive findings (e.g., delayed
parturition or whole-litter resorption with
TCE or trichloroacetate (TCA) (33,45,46),
difficulties in dose estimation, and the avail-
ability at similar or lower doses ofbetter doc-
umented effects, none ofthese studies were
addressed further.
As with other end points, there have been
limited findings ofdevelopmental effects
from TCE in human studies, but they are not
adequate for quantitative analysis (1). Some
animal studies focused upon specific end
Table 1. Oral studies to be evaluated quantitatively.
Effect
Eye
defects
LW/BW
Study citation
Narotsky et al. (45)
Tucker et al. (25)
LW/BW Buben and
O'Flaherty (56)
LW/BW Berman etal. (53)
Immune
function
Kidney
toxicity
Sanders etal. (26)
Maltoni et al. (52)
Further
quantitative
evaluation
NOAEL, BMD,
PK-NOAEL
NOAEL,
PK-NOAEL
LOAEL, BMD,
PK-LOAEL, PK-BMD
LOAEL, BMD,
PK-LOAEL, PK-BMD
NOAEL
NOAEL
Species Dose route and matrix
doses (mg/kg/day)
Rat Corn oil gavage: 0, 10, 32,
101, 320, 475, 633, 844, 1,125
Mouse Drinking waterwith emulphor:
0, 18, 217, 393, 660 males;
0, 18, 193, 437, 793 females
Mouse Corn oil gavage: 0, 100, 200,
400, 800, 1,600, 2,400, 3,200
Rat Corn oil gavage: 0, 50, 150,
500, 1,500
Mouse Drinking waterwith emulphor:
0, 18, 217, 393, 660 males;
0, 18, 193, 437, 793 females
Rat Olive oil gavage: 0, 50, 250
Duration
Gestation
6-15 days
6 months
5 days/week,
6weeks
14 days
consecutive
4 and 6
months
52 weeks
(follow-up
until natural
death)
PK, pharmacokinetic.
points for developmental malformations
using oral dosing (2). The two effects occur-
ring at the lowest oral doses are eye and
cardiac malformations. The cardiac mal-
formations studies are particularly difficult
to interpret because of the lack of clear
dose-response and temporal relationships
(i.e., exposures prior to pregnancy, during
pregnancy, or for both periods) (42).
Developmental studies with TCA and
dichloroacetate (DCA) also observed cardiac
malformation (47-50), but estimates of
maternal blood TCA levels do not appear
consistent between the TCA and TCE studies
(21). No effects were observed with other
TCE metabolites, notably chloral hydrate and
dichlorovinylcysteine (DCVC) (49,50).
Clearly, additional research is required to
determine ifthis effect is repeatable in other
laboratories and to better characterize its
dose-response behavior. Several studies ofeye
malformations have evaluated offspring of
pregnant mothers given a broad range ofcorn
oil gavage doses of TCE (10-1,500
mg/kg/day) (31,45). Sprague-Dawley rats, a
strain susceptible to this effect, were observed
to have eyes ofreduced size. Oral gavage with
TCA or DCA also has been reported to lead
to eye malformation (46,48). A positive
dose-response was observed in these studies
and theywere analyzed quantitatively (45).
Studies ofhumans exposed to TCE either
in drinking water or through accidental inges-
tion provide no evidence for kidney disease
(1). A study reporting increased urinary tract
infections in children included no direct mea-
sures ofkidney function (51). Kidney toxicity
in male and female rats (50-1,000
mg/kg/day) and mice (1,000 and 2,000
mg/kg/day) has been observed in chronic
corn oil gavage studies (22-24,52).
Subsequent to observing effects at the end of
the 2-year study, a 90-day study in F344 rats
was reevaluated and very mild indications of
toxic nephrosis were observed (23). Although
short exposures produced increased kidney
weight, it is unclear ifthis represents a reliable
indicator of chronic toxicity (53,54). A
chronic study in rats reporting kidney toxicity
was evaluated quantitatively (52).
Very limited data are available regarding
liver toxicity in humans from oral exposures
(1). Case studies ofingestion include one that
reports liver damage and several that do not.
Liver effects in animals are the best-character-
ized noncancer end point associated with
TCE (2). Numerous measures ofeffects have
been reported including alterations in liver-
to-body weight ratio (LW/BW) (25,54-61),
largely due to hypertrophy and some hyper-
plasia (54,58), peroxisome proliferation,
altered serum levels of liver enzymes, and
histopathologically observable changes
including necrosis. Some ofthese effects (e.g.,
LW/BW, peroxisome proliferation) are not
typically considered adverse effects by them-
selves, while others are (e.g., histopathology).
Effects in rats were less pronounced than
those in mice (54,58). No histopathology
was reported in chronically exposed rats
(22,24), which is notable because the doses
used (500 and 1,000 mg/kg/day) cause
increased LW/BW in shorter exposures; e.g.,
Berman et al. (53). Data for noncancerous
liver changes in mice exposed for a lifetime
are not available because the studies only
reported liver cancers (22,23). The 6-month
drinking water study in mice reported that
gross pathology was unremarkable, although
some animals had fatty infiltration (25).
Exposure to TCE by oil gavage appears to
produce greater and more severe liver effects
than exposures without oil (61). Peroxisomal
proliferation is one factor contributing to the
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increase in LW/BW (57,58). Alterations in
histopathology or leakage ofliver enzymes
into serum have been reported at higher doses
in mice and rats exposed for relatively short
periods (53,54,56,58,59,61). The altered
oxidative environment occurring with peroxi-
some proliferation may also play a role in the
liver damage indicated at high doses by mea-
sures such as leakage ofserum enzyme levels.
LW/BW is a reasonable candidate as a
sensitive early indicator for subsequent toxic-
ity for risk assessment purposes. However,
there are significant questions about the
effects of corn oil, the role of peroxisomal
proliferation, the linkage between LW/BW
and other measures of liver toxicity, and
interspecies comparisons. Additional data
would be desirable for longer duration expo-
sures to lower doses to further demonstrate a
linkage between this early response and later
liver toxicity. The 6-month drinking water
study, which might be considered the most
relevant exposure and duration, unfortunately
only reported the doses at which liver effects
were observed, not the LW/BWvalues; it was
considered further (25). Two other studies
reporting altered LW/BW ratios also were
evaluated quantitatively (53,56).
Selection ofInhalationStudies
Most ofthe toxicity end points observed in
oral studies have also been observed with
inhalation exposures. The end points dis-
cussed include neurotoxicity, immunotoxic-
ity, reproductive toxicity, developmental
malformations, kidney toxicity, and liver tox-
icity. A summary table lists the studies that
were selected for further evaluation (Table 2).
Most chronic inhalation studies reported only
cancer end points, but Maltoni et al. also
reported noncancereffects (52,62).
Inhalation ofTCE is well known to have
neurological effects both in humans and in
animals, hence its use as an anesthetic (1,63).
Acute and occupational studies ofbehavioral
effects in humans exposed at moderate con-
centrations (100-200 ppm) report no effects
or changes in a variety ofneurological mea-
sures (1,63). At higher concentrations,
effects become obvious, with anesthesia
occurring around 3,000 ppm. Studies of
workers chronically exposed to TCE report a
range of neurological effects. A few case
studies have reported cardiac arrhythmia or
other cardiac effects after unspecified or high
inhalation exposures, while a briefexposure
to 200 ppm for 2.5 hrhad no effects (1).
Studies in animals have focused upon
physical, e.g., biochemical, histological, or
electrophysiological effects (64-69) or behav-
ior changes (68,70-72), but rarely both.
Some studies have correlated effects with
plasma levels ofTCE or trichloroethanol
(TCOH) (73,74).
A study of heart rate and electro-
encephalographic responses during wake and
sleep periods reports alterations at 50, 100,
and 300 ppm in rats exposed for 6 weeks
(75). Measurements were made during the
exposure and during a 22-hr postexposure
period. Statistically significant changes were
observed at several doses during or post-
exposure for time spent in wakefulness, slow-
wave sleep, and heart rate. This study is
evaluated quantitatively below because it
reports effects following subchronic exposure.
Short-duration studies at high concentra-
tion (near 1,000 ppm) have focused on end
points including effects on trigeminal nerves
and hearing loss (1). Animal studies using
moderate concentrations and exposure dura-
tions of 5 months or less report effects at
approximately the same range as reported with
humans. These studies provide supporting evi-
dence for effects following subchronic expo-
sure at doses similar to and higher than the
Arito et al. (75) study. No neurotoxicity data
areavailable fromchronic inhalationstudies.
A fewstudies report decreases in mortality
from respiratory infections and other diseases
partially indicative ofhuman immune status,
though none include biochemical or cellular
measures of immune system functions
(1,4,76). Acute studies of immune function
demonstrated effects in animals exposed by
inhalation (77-79). Bacterial challenge of
CD-1 mice following 3-hr TCE exposures
(2.5-200 ppm) produced a dose-related
increase in mortality due to compromised
pulmonary immune functions including
decreased phagocytosis by lung macrophages
(77-79). A repeated 5-day exposure pro-
duced an increase that was substantially less
than predicted from the assumption that the
Table 2. Inhalation studies to be evaluated quantitatively.
Further quantitative Exposure
Effect Study citation evaluation concentration (ppm) Species Duration
Electroencephalo- Arito et al. (75) LOAEL, BMD, 50, 100, 300 Rat 8 hr/day, 5days/
graphic changes, PK-LOAEL, PK-BMD week, 6 weeks
heart rate
LW/BW Kjellstrand LOAEL, BMD, 37, 75, 150, 300 Mouse Continuous, 30-day
et al. (92) PK-LOAEL, PK-BMD
Kidney toxicity Maltoni NOAEL, BMD, 100, 300, 600 Rat 7 hr/day, 5 days/
et al. (52) PK-LOAEL, PK-BMD week, 104 weeks
concentration-time product would be con-
stant (77). In the absence ofdata for longer
exposures and given the lack of a constant
concentration-time product, it is difficult to
extrapolate these acute effects for evaluating
potential chronic toxicities, although these
data might be considered supporting data
when evaluating options for RfCs derived
from other studies.
No reproductive studies in humans are
available (1). Studies in animals reported
effects at concentrations of 500 ppm or
higher; they will not be evaluated further
because other end points are reported to
occur at lower concentrations. Data for devel-
opmental toxicity in humans are limited and
inconsistent (1,80-82). An increase in
delayed ossification and whole-litter resorp-
tions was observed following exposure ofrats
to 100 ppm TCE (83). Other animal studies
reported no statistically significant increases
in malformations with concentrations ranging
from 100 to 1,800 ppm (83-86).
Several studies ofworkers have reported
limited findings ofrenal toxicity (1). Kidney
toxicity was reported in an inhalation study
exposing Sprague-Dawley rats to 0, 100, 300,
or 600 ppm ofTCE (62). A dose-related
trend for renal megalonucleocytosis was
observed in male rats. This finding is in con-
trast to the oral gavage data that showed
effects in both sexes of rats and in mice
(23,24). Maltoni et al. (62) was evaluated
quantitatively.
There are little human data reporting
pulmonary toxicity (1). A study in rats
exposed for up to 90 days to 700 ppm TCE
reported no histopathological changes (87).
Vacuolation of Clara cells and decreased
cytochrome P450 activity were reported in
female mice exposed at concentrations of
20-2000 ppm, though no quantitative data
were presented (88). This effect was not
observed in rats. It is believed to be specific to
mice because ofaccumulation ofchloral in
Clara cells. This study will not be analyzed
further because of the limited documenta-
tion, the apparent species specificity, and the
availability of studies at similar doses for
other effects.
Although liver toxicity is frequently
reported in animal studies with TCE, there is
more limited evidence for liver effects in
humans (1,3). No gross pathological liver
effects were observable in several species (rats,
guinea pigs, rabbits, dogs) exposed to 730
ppm (8 hr/day, 5 days/week, for 6 weeks)
(87). Dose-related (37-300 ppm) increases in
LW/BW in mice were reported without more
direct measures ofliver toxicity (89-92). The
effect in mice was largely reversed in 30 days
following the 30-day exposure. Ethanol expo-
sure increased liver toxicity because ofTCE
exposures of 500 ppm or greater, reflecting,
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in part, increased metabolism by cytochrome
P4502E1 at this high concentration (93,94).
The dose-response data ofKjellstrand et al.
(91) were evaluated quantitatively based
upon the interpretation that LW/BW
changes were sensitive early indicators of
potential liver toxicity.
Quantitative Dose-Response
Analysis
Each study previously identified as a potential
critical studywas evaluated using one or more
methods for developing toxicity values
(6,11). These methods ranged from the
default approach used in the absence ofany
information except a LOAEL to approaches
that incorporate mode-of-action and dosi-
metry data to assist in extrapolating between
exposure regimens, dose levels, study dura-
tions, andspecies.
Dose-ResponseAnalysisMethods
All the studies selected for dose-response
analysis evaluated effects ofTCE exposure on
laboratory animals. For each study the
NOAEL or LOAEL was determined and the
BMD calculated, all based on the exposure
doses used in the studies. These values were
then adjusted to daily dosing or continuous
inhalation exposure based on an assumption
that the concentration-time product would
be constant (11). To calculate the human
equivalent concentration (HEC) for the
NOAEL or BMD, the value adjusted to con-
tinuous exposure was multiplied by 1.0
because the value for the blood-to-air parti-
tion coefficient for animals was greater than
that forhumans.
Uncertainty factors were then applied to
obtain the RfD or RfC. These uncertainty
factors are intended to account for estimating
a NOAEL from a LOAEL (referred to as L),
extrapolating to chronic exposure from sub-
chronic exposures (referred to as S), extrapo-
lating from animals to humans (referred to as
A), accounting for the variability of the
human population and potential sensitive
subpopulations (referred to as H), and limita-
tions of the available toxicity database
(referred to as D). These uncertainty factors
are assumed to be independent, so they are
multiplied together. Each uncertainty factor
usually has a value up to 10, though this
appears to be overly conservative when multi-
ple factors are used (13). Therefore, policy
choices have been made to limit the total
uncertainty factor to 3,000 when four factors
are used rather than 10,000 (11).
Exposure dose is frequently complexly
related to responses, so it is advantageous to
use mode-of-action information to select
appropriate internal dose metrics reflecting
the biologically effective dose. The NOAEL
or BMD in terms ofinternal exposure (i.e.,
in units of the dose metric) was estimated
using the animal physiologically based phar-
macokinetic (PBPK) model. The human
PBPK model was used to estimate the exter-
nal doses for continuous or repeated human
exposure (i.e., inhalation or drinking water,
respectively) that would result in the appro-
priate internal dose metrics. Because the
human model was linear for all the dose met-
rics over very broad dose and concentration
ranges, essentially identical results would be
obtained whether the uncertainty factors
were applied to the internal dose metric or
the associated exposure dose estimated using
the PBPK model.
Uncertainty factors also largelyfit into the
exposure:dosimetry:mode-of-action:response
framework, though the database uncertainty
factor is a policy response to data limitations
and essentially falls outside this framework.
When mode-of-action information was used
to select a dose metric, it also helped inform
issues ofextrapolation from a LOAEL to a
NOAEL, responses following shorter expo-
sure to anticipated responses with chronic
exposure and between animals and humans.
There is less frequently information relevant
to estimating human variability (95). In the
RfC methodology, calculation ofthe HEC is
assumed to account for the pharmacokinetic
differences between species, so the uncer-
tainty factor for interspecies extrapolation (A)
has, at most, a value of3. Absent additional
mode-of-action information, a similar
assumption was used here when internal dose
metrics were estimated for oral studies (i.e.,
A = 3). Specific examples ofhow this might
be done are discussed below in the evaluation
ofspecific end points for TCE. In general,
this approach attempts to maximize the use of
scientiflc information in a semiquantitative
manner by adjusting the uncertainty factors
to reflect data that are not captured in a more
extensive biologically based modeling
approach.
PBPKModelforTCEandMetabolites
The PBPK model described the pharmaco-
kinetics in mice, rats, and humans ofTCE
and its toxicologically important metabolites:
TCOH, TCA, DCA, and DCVC (96,97). It
describes oral and inhalation exposures. A
range ofpossible dose metrics can be obtained
including: area under the curve (AUC) in
blood for TCE (designated AUCTCE), TCA
(designated AUCTCA), and TCOH (desig-
nated AUCTCH). Other dose metrics can
also be estimated such as total metabolites
normalized to body weight (designated
AMET), peak concentrations for TCE (desig-
nated CTCE), TCA (designated CTCA) and
TCOH (designated CTCOH), and an esti-
mate of metabolism through the DCVC
pathway (designated KTOX). The model was
exercised using Advanced Continuous
Simulation Language (ACSL, Mitchell &
GauthierAssociates, Concord, MA).
Several notable kinetic differences
between the species have been observed in the
experimental literature and were included in
this model. Mice metabolize TCE much
more effectively than either rats or humans.
The two major metabolites ofTCE are TCA
and TCOH. In humans, TCOH appears to
undergo extensive enterohepatic recirculation
of its glucuronide conjugate resulting in a
much longer half-life for TCOH in humans
compared to the rodents. Because TCOH
can be metabolized back to TCA, this also
results in a much longer half-life for TCA in
humans compared to rodents.
BenchmarkDoseMethods
An alternative to the identification of a
NOAEL is to calculate a BMD from the
dose-response data (15-17). Three different
kinds ofdata were used in BMD analyses:
quantal, continuous, and nested quantal (i.e.,
litter) data. For each type ofdata, different
methods were used. The quantal data were
evaluated using two programs, THRESH and
THRESHW (KS Crump Group, ICF
Consulting, Ruston, LA). THRESH fits a
polynomial model and THRESHW fits a
Weibull model to the data (15). The continu-
ous data were analyzed with BENCH_C (KS
Crump Group, ICF Consulting, Ruston, LA),
which fits the Power and Weibull models
(16). In addition, a quadratic model for ana-
lyzingcontinuous datawas used (98) forcom-
parative purposes with the liver data ofBuben
and O'Flaherty (56). This program was gen-
erously provided by R. L. Kodell (National
Center for Toxicology Research, Jefferson,
AK). Finally, the litter incidence data were
analyzed using TERAMOD and TERALOG
(KS Crump Group, ICF Consulting, Ruston,
LA) (99); these models account for possible
extra-binomial variation associated with
nested responses. Regardless ofthe type of
data, the models considered express probabil-
ityofresponse as afunction ofdose.
The BMD analysis for each data set used
two models to estimate the maximum likeli-
hood estimate or best fit (MLE) and its statis-
tical lower bound (BMDL) for a 10%
benchmark response (BMR). For continuous
data, the 1% region ofthe tails ofthe distrib-
ution ofcontrol responses was assumed to be
abnormal, i.e., P0 was 0.01. Other values for
BMR and PO were investigated and are pre-
sented in an extended version ofthis analysis
(21). Lowervalues for PO result in higheresti-
mates for the MLE and BMDL. As the value
ofPO decreases, a smaller portion ofthe con-
trol distribution is considered abnormal and
the acceptable variation for the continuous
end point (e.g., LW/BW) is larger.
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limited here to explaining judgments involved
in this process; absent data, typical U.S.
Environmental Protection Agency (U.S. EPA)
default assumptions were used, as indicated in
Table 4.
EyeMalformation
Comparing mean responses, only the highest
dose group, 1,125 mg/kg/day, was statistically
different from the controls (45). Trend testing
to find the no-statistical-significance-of-trend
Table 3. NOAELs, LOAELs, and BMDs for oral studies based on exposure doses.
NOAEL LOAEL MLEa BMDLb
Effect Study citation (mg/kg/day) (mg/kg/day) (mg/kg/day) (mg/kg/day)
Eye malformations Narotsky et al. (45) 32 101 777, 751 c 505, 501 c
LW/BW Tucker et al. (25) 18 217 ND ND
LW/BW Buben and ND 100 20, 489d 14, 341d
O'Flaherty (56)
LW/BW Berman et al. (53) ND 50 3,309, 1,403d 742, 650d
Immune function Sanders et al. (26) 200 400 ND ND
Kidney toxicity Maltoni et al. (52) 50 250 105e 70e
ND, not determined in study. 'Maximum likelihood estimate for 10% likelihood of response. bLower-bound estimate for 10% likeli-
hood of response. dBMD estimates for P0 = 0.01, and BMR = 0.1; results for Weibull and Power models. Unadjusted to continuous
exposure. CBMD estimates for BMR = 0.1; results for Teralog and Teramod models. °BMD estimates for BMR = 0.1; results for
Polynomial Quantal model.
Table 4. Summary of RfDs for all end points.
NOAEL/ Exposure Uncertainty Basis for Dose metric RfDd
Model BMD adjustment factor uncertainty factor adjustment (mg/kg/d)
Eye malformations-
Narotsky et al. (45)
NOAEL 32a 100 H:10, A:10 1 0.3
BMDL 500a 100 H10, A:10 1 5
LW/BW-Tucker et al.
(25)
NOAEL 18a 100 H:10, A:10 1 0.2
PK-NOAEL 570b 30 H:10, A:3 479 0.04
LW/BW - Buben and
O'Flaherty (56)
LOAEL 100a 5/7 300 H:10, A:10, L:3 1 0.2
BMDL, Weibull 14a 5/7 100 H:10, A:10 1 0.1
BMDL, Power 341a 5/7 100 H:10, A:10 1 2
PK-LOAEL 573b 30 H:10, A:1, L:3 479 0.04
PK-BMDL, Weibull 551b 10 H:10, A:1 479 0.12
PK-BMDL, Power 196b 10 H:10, A:1 479 0.04
LW/BW- Berman et al.
(53)
LOAEL 50a 300 H:10, A:10, L:3 1 0.2
BMDL, Weibull 742a 100 H:10, A:10 1 7
BMDL, Power 650a 100 H:10, A:10 1 7
PK-LOAEL 118b 30 H:10, A:3 479 0.008
PK-BMDL, Weibull 308b 10 H:10, A:1 479 0.06
PK-BMDL, Power 239b 10 H:10, A:1 479 0.05
Immunotoxicity - Sanders
et al. (26)
NOAEL 200a 100 H:10, A:10 1 2
Kidney toxicity- Maltoni
et al. (52)
NOAEL 50a 5/7 100 H:10, A:10 1 0.4
BMDL 70a 5/7 100 H:10, A:10 1 0.5
PK-NOAEL 85c 30 H:10, A:3 1.54 2
PK-BMDL 233c 30 H:10, A:3 1.54 5
Abbreviations: A, animal-to-human uncertainty factor; H, human variability uncertainty factor.'mg/kg/day exposure dose metric.
bmg-hr/L internal dose metric - AUCTCA. cmg/kg internal dose metric - KTOX. dRfD is obtained by multiplying NOAEL/BMD by the
adjustment for exposure and dividing by uncertainty factorand the dose metricadjustment.
(referred to in the literature as NOSTASOT)
dose found a NOAEL of32 mg/kg/day and a
LOAEL of 101 mg/kg/day (2). These values
are well below the dose of 1,125 mg/kg/day
that was the only dose group statistically sig-
nificantly different from controls, as reported
by the authors using a test for comparison of
means. BMDs obtainedwith two models were
very similar using exposure doses (Table 3,
Figure 2). The BMDLs are much higher than
the NOAEL because the observed response
was so small. The developmental exposures
were daily, so no dose-averaging adjustments
were made (Table4).
LW/BW
While a NOAEL of 18 mg/kg/day was
reported in the drinking water study (25),
only LOAELs were reported in the other two
studies (Table 3). No BMD was estimated for
the drinking water data because numerical
values of LW/BW were not reported (25).
The MLEs obtained with exposure doses
from the mouse study (56) were highly
dependent on the choice of model. A qua-
dratic model appears to better fit the low-dose
mouse data, as illustrated in Figure 3A. The
MLE and BMDL were 201 and 173
mg/kg/day, respectively, which fall in
between those from the other two models.
The wide variation in BMD values requires
qualitative judgfnents for the selection ofthe
most appropriate model. The rat study (53)
results were less model dependent. No adjust-
ments for dosing frequency were required for
the Tucker et al. and Berman et al. studies
(25,53). The gavage study used 5-day/week
dosing; the LOAEL was adjusted by 5/7 to
obtain an RfD (56).
Selection of changes in LW/BW as a
potential critical end point was based on its
role as an early event in the toxicity process
and a sensitive indicator of potential liver
effects observed at later times (2). Therefore,
based upon the mode-of-action argument
that this early event is an indicator of toxici-
ties that develop later, no adjustments for the
duration ofexposure (uncertainty factor S)
would be needed, regardless of the study
duration. Similarly, the value of3 was used
for L, based on the LOAEL being a minimal
change in an effect that is not actual toxicity
but a sensitive indicator. The size of the
changes was small, just 12% increase in
LW/BW in the Buben and O'Flaherty (56)
and 7% in the Berman et al. study (53).
Immunotoxicity
Impaired immune functions were observed
in mice, particularly in females, exposed to
TCE in drinking water for 4 months (26).
The antibody-forming (plaque-forming) cell
assay had a LOAEL of 400 mg/kg/day in
females at 4 months and males at 6 months;
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Oral Studies: Dose-Response
Based on Exposure Dose
Metric
Six studies reporting four different toxic
effects were evaluated quantitatively (Table 1).
The NOAELs, LOAELs, and BMDs for each
study are reported in Table 3. Other adjust-
ments (i.e., exposure regimen, dose metric,
and uncertainty factors) and the RfDs derived
are summarized in Table 4. Description is
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Figure 2. Eye malformations: maximum likelihood fits to
exposure dose. (BMR = 0.1). Data from Narotsky and
Kavlock (31).
Figure 3. Liver effects: model fits to LW/BW using alternate dose metrics. (A) exposure doses; (B) AUCTCA. Data
from Buben and OFlaherty (56). The observed mean data points and their standard deviations are illustrated with
lines for several fitted models.
the NOAELs were 200 mg/kg/day. The
delayed hypersensitivity assay had a LOAEL
of20 mg/kg/day in female mice at 4 months
compared to the vehicle-treated control, but
there was a large difference between the
vehicle-treated control and naive control. At
6 months, the LOAEL for this assay was 800
mg/kg/day and the NOAEL was 400
mg/kg/day in females. No effects were seen
in males. Taken together, these assays are
supportive of a LOAEL of 400 mg/kg/day
and a NOAEL of200 mg/kg/day (Table 3).
The BMD method was not used for the
evaluation ofthe data from the immunotox-
icity study. The dose-response relationships
varied for each assay, and it was felt that no
single assay should be used alone to deter-
mine the dose-response relationship for
estimating a BMD.
There was no dose-averaging adjustment
because exposure was daily (Table 4). No
adjustments for the duration ofexposure were
made. There appeared to be a greater effect at
4 months than at 6 months, suggesting that
the mode of action may not be cumulative
over longer periods oftime as is assumed in
the use ofthe subchronic-to-chronic uncer-
tainty factor. This may partly reflect changes
in immune system function over time.
KidneyToxicity
Male Sprague-Dawley rats developed kidney
toxicity when dosed with 250 mg/kg/day, 5
days/week for 52 weeks but not at the
NOAEL of 50 mg/kg/day [Table 3, (52)].
This data set is marginally acceptable for the
BMD method because there is only a single
positive dose (Figure 4). However, it was
evaluated because based upon studies in five
other rat strains (23,24), a response ofnearly
100% is potentially obtainable; i.e., the
46.7% response at 250 mg/kg is a valid esti-
mate of the percent of total response. The
polynomial model appears to provide a more
reasonable fit, approximating a straight line
between the NOAEL and LOAEL. The
Weibull model predicts no response until a
relatively high dose; response then increases
very rapidly. The Weibull model might be
considered inadequately health protective
given that there is no mode-of-action infor-
mation to justify assuming virtually no
response until doses near those giving a 50%
response.
The NOAEL and BMD were multiplied
by 5/7 to adjust to daily dosing (Table 4).
The study dosed for a significant portion of
lifetime, so no adjustment was made for dura-
tion. Animals were observed till the time of
natural death (intended to allow about a year
for postexposure expression of tumors), so
some recovery from kidney toxicity might
have occurred in some animals.
Oral Studies: Incorporating
Pharmacokinetics and
Mode ofAction
The results of the dose-response analysis
using the internal dose metrics selected below
aresummarized in Table 4.
EyeMalformation
No hypotheses for modes ofaction have been
proposed for the eye malformation end point
that would assist in selecting the appropriate
internal dose metric. The teratogenicity
studies with TCA and DCA report increases
in microphthalmia and anophthalmia, sug-
gesting one or both chloroacids may con-
tribute to the effects observed with TCE
(46,48). TCE metabolism in the fetus would
be limited because cytochrome P4502E1 lev-
els are very low prior to birth and increase
greatly shortly after (100); circulating mater-
nal levels ofTCA or DCA would appear to
be the relevant chemical form. Comparison
ofthe AUCTCA at doses ofTCE and TCA,
which produced about 10% incidence ofeye
malformations in pups, found drastically dif-
ferent results. The AUCTCA estimated for
dosing with the LOAEL dose of 1,200
mg/kg/day ofTCA (46) was about 20,000
mg-hr/L, while TCE at 1,125 mg/kg/day
(45) produces an AUCTCA of405 mg-hr/L.
This discrepancy raises doubt that the levels
of TCA produced from TCE would be
adequate to cause the effect, although the rat
strains were different. Although most toxici-
ties associated with TCE arise from metabo-
lites, it is possible that changes in membrane
characteristics due to TCE itselfare responsi-
ble for the developmental effects because
development is highly dependent upon
cell-cell communications. It is also undeter-
mined ifthe effect results from the concentra-
tion ofchemical or a time-integrated measure
ofdose, such as AUC. Finally, in the absence
of models for both the developing rat and
human fetus, only dose metrics in the mater-
nal blood perfusing the placenta would be
feasible. Absent strong mode-of-action
hypotheses, no evaluations with internal dose
metrics are reported here. Variable results were
obtained when many potential pharmaco-
kinetic NOAELs were evaluated (21).
LW/BW
Alterations in the liver are believed to arise
from metabolites of TCE. Buben and
O'Flaherty found that total urinary metabo-
lites linearized their LW/BW data, so AMET
was one potential dose metric (56). This
dose metric would be consistent with effects
resulting from metabolism ofTCE, with no
adjustments for the pharmacokinetics of the
individual metabolites (i.e., short-lived vs
long-lived, etc.). However, analysis of the
data on LW/BW and enzyme changes fol-
lowing dosing with TCE and perchloroethyl-
ene suggests that AMET is not a satisfactory
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Figure 4. Kidney effects: model fits using oral exposure.
Data from Maltoni et al. (52).
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dose metric because it would predict that
TCA from perchloroethylene (60-90% of
urinary metabolites) was more potent than
TCA from TCE (about 10% of urinary
metabolites) (56).
Oral exposure to TCA produced
increased LW/BW, peroxisome proliferation,
and other effects associatedwith TCE, so it is
a candidate as the active metabolite
(101-105). A potential dose metric for TCA
is AUCTCA. This dose metric was obtained
by running the PBPK model for 336 or
1,008 hr and dividing the total dose metrics
for that time by 14 or 42 days, for the rat and
mouse studies, respectively, to obtain the
dailyaverageAUC (53,56).
Finally, several other dose metrics might
be relevant for the effects in mice or rats
including those for DCA. There was a lack of
data supporting human DCA production
from TCE, so itwas not possible to use PBPK
modeling to obtain an equivalent human
dose. In addition, estimates ofDCA produc-
tion in mice have been excessivelyhigh due to
analytical chemistryartifacts (106).
For liver effects there is a database from
which to develop information about the
mode ofaction in animals and humans. Only
information for TCE or its metabolites was
explicitly considered here. TCE has been
tested in mice, rats, gerbils, guinea pigs, rab-
bits, and dogs byoral or inhalation exposures.
It produces limited noncancer liver toxicity in
any ofthese species until doses approaching
the LD50 (lethal dose at 50%) are reached.
Similarly, the available data indicate that
TCE is not apotent liver toxicant in humans,
aswould appear to be predicted byAUCTCA
ifequal or greater pharmacodynamic sensitiv-
ities were assumed.
Because LW/BW alterations and other
liver effects are believed to involve the per-
oxisome proliferator-activated receptor
(PPAR), extrapolation of the response to
humans is not quantitatively straight-
forward. One approach to estimating the
interspecies pharmacodynamic (PD) extra-
polation was to compare rats and mice. Data
for LW/BW increases and alterations in
palmitoyl-coenzyme A oxidase activity (a
marker for peroxisomal proliferation)
following drinking water exposure to TCA
for 10 days showed rats to be much less
responsive than mice based upon estimated
AUCTCAs (101). Another study reports
rats to be more sensitive than mice for
palmitoyl-coenzyme A oxidation following
10 days dosing with TCA in corn oil. When
AUCTCA is estimated for this study, the
rats are about 1.5 times more responsive.
DeAngelo et al. found that corn oil
increased response in rats compared to an
aqueous vehicle (101). Therefore, there are
two issues for extrapolating to humans, their
relative sensitivity and the effects ofcorn oil
in the rodents versus drinking water in
humans. The available molecular and phar-
macological data have not identified humans
with a fully active PPAR as found in the
mouse. It is likely that humans are more like
rats than mice, so these data do not support
the standard assumption that humans are
more sensitive than the most sensitive
rodents. Analysis ofthe interspecies extrapo-
lation for other peroxisomal proliferators,
Table 5. Summary of RfCs for all end points.
NOAEL/ Exposure Uncertainty Dose metric
Model BMD (ppm) adjustments factor Basis ofuncertaintyfactor adjustment RfC
Neurological effects -Arito etal. (75)
LOAEL 50 8/24 x5/7 100 H:10, A:3, L:3 0.1
BMDLs
HR Weibull 32 8/24 x5/7 30 H:10, A:3 1 0.3
HR Power 122 8/24 x5/7 30 H:10, A:3 1 1.0
W Weibull 8 8/24 x5/7 30 H:10, A:3 1 0.06
W Power 130 8/24 x5/7 30 H:10, A:3 1 1.0
SWS Weibull 8 8/24 x 5/7 30 H:10, A:3 1 0.06
SWS Power 78 8/24 x 5/7 30 H:10, A:3 1 0.6
PS Weibull 223 8/24 x5/7 30 H:10, A:3 1 2
PS Power 114 8/24x5/7 30 H:10,A:3 1 0.9
PK-LOAELs: CTCOH 1.2 30 H:10, A:1, [:3 0.132 0.3
PK-BMDLs: CTCOH
HR 0.99 10 H:10, A:1 0.132 0.8
W 0.64 10 H:10, A:1 0.132 0.5
SWS 0.57 10 H:10, A:1 0.132 0.4
PS 2.2 10 H:10,A:1 0.132 1.7
LW/BW - Kjellstrand et al. (92)
LOAEL 37 100 H:10, A:3, L:3 1 0.4
BMDL
Female Weibull 32 30 H:10, A:3 1 1
Female Power 21 30 H:10, A:3 1 0.7
Male Weibull 5 30 H:10, A:3 1 0.2
Male Power 24 30 H:10, A:3 1 0.8
PK-LOAEL 2,789 30 H:10,A:1, L:3 232 0.4
PK-BMDL
Female Weibull 2,496 10 H:10, A:1 232 1
Female Power 2,067 10 H:10, A:1 232 0.9
Male Weibull 1,214 10 H:10, A:1 232 0.5
Male Power 1,122 10 H:10, A:1 232 0.5
Kidneytoxicity - Maltoni etal. (52)
NOAEL 100 7/24 x5/7 30 H:10, A:3 1 0.7
BMDL 203 7/24 x 5/7 30 H:10, A:3 1 1
PK-NOAEL 39 30 H:10, A:3 0.74 2
PK-BMDL 370 30 H:10, A:3 0.74 17
Abbreviations: HR, heart rate; PS, paradoxical sleep; SWS, slow-wave sleep; W, wakefulness.
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particularly the hyperlipidemic drugs would
assist in further determining the appropriate
interspecies extrapolation. These data indi-
cate that the value ofthe uncertainty factor
for interspecies extrapolation should be no
greater than 1 and potentially less than that.
KidneyToxicity
Kidney toxicity is believed to develop from
metabolites formed through the glutathione
conjugate pathway (107). Therefore, the
model was used to estimate a dose metric for
DCVC in the kidney, KTOX. KTOX repre-
sents the total production ofthe thioacetylating
intermediate from DCVC divided by the vol-
ume ofthe kidney. The dailyvalue for KTOX
was obtained averaged over a 1-week (7-day)
period. Limited information is available about
thepharmacodynamic processes involved in the
kidney toxicity. Both mice and rats developed
kidneytoxicityin corn oil gavage assays and the
mice appeared somewhat more sensitive
(22-24). In the absence ofother information,
the default assumption was made that humans
are 3-fold more sensitive than animals for the
PD processes leadingtokidneytoxicity.
Inhalation Studies:
Dose-Response Based
on Exposure Dose Metric
Three studies reporting different toxic effects
were evaluated quantitatively (Table 2). The
NOAELs, LOAELs, and BMDs for each
study are reported in Table 5, as are other
adjustments (i.e., exposure regimen, dose met-
ric, and uncertainty factors) and the RfCs
derived. Description here is limited to explain-
ing judgments involved in this process; other-
wise standard U.S. EPA default assumptions
were used, as indicated in Table 5.
NeurologicalEffects
Exposure dose-based NOAELs, BMDs, and
RfCs were derived from measurements of
electroencephalographic activity and heart rate
made in a 32-hr period during the second,
fourth, and sixth weeks ofexposures in freely
moving male rats implanted with electrodes
(75). Three measures were derived from elec-
troencephalographic measurements-wakeful-
ness, slow-wave sleep, and paradoxical sleep;
heart rate was measured independently. All
four measures were statistically different from
control levels at the lowest dose used (LOAEL
= 50 ppm); a NOAEL was not determined.
The exposure dose-based BMDs vary by as
much as 17-fold using the two models
(Weibull and Power) (Figure 5A, Table 5).
The exposure-based LOAEL and BMD values
were lowered to estimate continuous exposure
from the 8-hr/day, 5-day/week exposures. The
LOAEL was considered to reflect a minimal,
though statistically significant, effect, so the
uncertainty factor (L) was 3 instead of 10.
LW/BW
Increases in LW/BW, a liver toxicity end
point, were statistically significant in both
male and female mice at all dose levels tested
(91). The LOAEL was used without adjust-
ment because the exposure was to 37 ppm
continuously for 30 days. Although this is a
LOAEL, it is for a minimal effect, so the
uncertainty factor (L) was 3 instead of 10. In
contrast to the identical LOAELs for female
and male mice, the BMDs differ because of
the different shapes of the dose-response
curves (Table 5). The females showed a basi-
cally linear increase with dose in LW/BW,
while the male dose response was concave.
KidneyToxicity
Kidney toxicity was reported in rats at the
two higher exposure concentrations, and a
NOAEL was found at the lowest concentra-
tion of 100 ppm (52). For the inhalation data
sets from the kidney toxicity study, the poly-
nomial and Weibull models gave very similar
fits and BMD estimates. To be consistent
with the oral data, the results from fitting the
polynomial model were used here. The
NOAEL or BMDL were multiplied by 7/24
and 5/7 to adjust to continuous dosing.
Inhalation Studies:
Incorporating Pharmacokinetics
and Mode ofAction
The results of the dose-response analysis
using the internal dose metrics selected below
are summarized in Table 5.
NeurologicalEffects
There are two major hypotheses for the mode
ofaction ofTCE in the causation ofneuro-
logical effects, activity ofparent TCE, or the
metabolite, TCOH. Chloral hydrate might
also be active, but it is generally believed that
TCOH is the active species in choral hydrate
anesthesia (108). EitherAUC or peak concen-
trations might be reasonable dose metrics, but
as illustrated in Figure 5C, the CTCOH lin-
earized the data, suggesting that TCOH is the
active agent. Therefore, results are reported
with this dose metric. The dose metric was
obtained by estimating with the model the
daily concentration during the 5 exposure
days of the sixth week of the experiment.
Evaluation ofother dose metrics for TCE and
TCOH are reported elsewhere (21).
Although mode-of-action data were limited
for the neurological effects, there was some
comparable data in humans and rodent studies.
These data provided a basis for comparing the
pharmacodynamic responsiveness ofthe two
species. Dose metrics at the LOAELs or
NOAELs ofthe human and rat studies were
compared (Table 6). One potential limitation
ofthe human data was that all the studies use
exposures lasting 1 day or, in onestudy, 5 days.
Whether this is a significant limitation is
undear because Arito et al. report some effects
show a dependence on repeated exposures,
while others do not, and other effects were
dependent upon repeated exposures but not on
exposure concentration (75). The internal dose
metrics modeled forthehuman studies aregen-
erally equal to or greater than those in the rat
study, particularly for TCOH. Exceptions
occur in the dose metrics for TCE. Because of
the slower dearance ofTCOH in humans aris-
ing from enterohepatic recycling, the modeled
peak concentration and AUCTCH is consis-
tentlyhigherthan thosefoundforthe rat.
These data do not support the default
assumption that humans are more sensitive to
TCE exposure than the rat. The studies show
little or no effect in humans with modeled
internal dose metrics equal to or greater than
those modeled for the rat exposed at a concen-
tration producing minimal effects. Therefore,
this combined pharmacokinetic and mode-of-
action analysis support assuming the two
species equivalently sensitive (i.e., the value of
A would be 1.0) for these effects when using
CTCOH as the internal dose metric.
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Figure 5. Neurological effects: model fits to wake-
fulness data using alternate dose metrics. (A) exposure
concentrations; (B) venous TCE (CVTCE); (C) blood TCOH
concentrations (CTCOH). Data from Arito et al. (75). The
observed mean data points and their standard devia-
tions are illustrated with lines for several fitted models.
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Table 6. Comparison ofdosimetrics from rat and human neurological studies.
Exposure
Study concentration (ppm) Effects CVTCE CTCOH AUCTCE AUCTCH
Rat study
Arito et al. (75) 50for 8 hr/ Electroencephalographic 1.3 1.2 13 10
day LOAEL changes in sleep and
wakefulness; decreased
heart rate
Human studies
Stewart et al. (109) 200 for7 hr Mild fatigue and sleepiness 3.8 15.5 34 206
for 5 days on days 4 and 5
Nomiyama and 27 for4 hr Slighttrend toward 0.4 1.4 2.4 14
Nomiyama (110) 81 for4 hr slower pulse rate 1.3 4.2 7.4 43
Windemuller and 200 for 2.5 hr No effect on heart 3.0 6.5 12 66
Ettema (111) orbreathing rate
Salvini et al. (112) 110 for8 hr Decreased performance on 1.9 9.8 20 127
psychophysiological tests
Konietzko etal. (113) 95for4 hr No effect on heart rate 1.5 4.9 8.7 51
CVTCE, concentration ofTCE in blood.
LW/BW
The AUCTCA derived from the data set of
the liver toxicity study was obtained by esti-
mating with the model the daily average
AUCTCA during the 30-day continuous
exposure. As described previously for oral
exposures, information on the mode ofaction
does not support the default assumption that
humans are more sensitive than animals for
liver effects, so a value of 1 was used for the
interspecies extrapolation based upon internal
dose metrics. A 10-fold adjustment for H was
also made, although the mice may essentially
be equivalent to a sensitive subpopulation
with afully active PPARthat has notyet been
identified in humans.
KidneyToxicity
KTOX was evaluated for inhalation expo-
sures as it was for oral exposures. The average
daily value for KTOX was obtained by aver-
aging over a 1-week (7-day) period.
Discussion and Summary
The process ofdeveloping dose-response val-
ues is an iterative one that typically is
repeated as additional scientific information
becomes available. The exposure:dosimetry:
mode-of-action:response framework des-
cribed in this paper organizes the process and
promotes consistency between end points.
This framework facilitates incorporating sci-
entific data and assists scientists conducting
research by defining methods bywhich scien-
tific data can be used in risk assessment.
These methods include: BMDs derived by
empirical curve fitting, pharmacokinetic
models reflecting the processes important for
different chemicals and their metabolites, use
of uncertainty factors to semiquantitatively
adjust for incompletely described pharmaco-
kinetic and pharmacodynamic processes, and
eventually more complete pharmacodynamic
models that quantitatively describe critical
steps in the mode ofaction leading to toxicity.
The choice of methods used varies in
response to the availability ofdata as well as
differences in the relevant biological
processes. Appropriate dose-response analysis
requires a consistent framework for organiz-
ing information and analyses, not a single
universally applied analytical method.
The initial step in the process is to review
the literature and choose the studies that
might be used as critical studies for each toxic
end point. The supporting literature must be
reviewed to determine the availability of
hypotheses for the mode ofaction leading to
the various effects. The NOAELs or BMDs
can be determined using exposure doses or
internal dose metrics; absent mode ofaction
and pharmacokinetic information, analyses
based on exposure dose represent an appropri-
ate default approach. When feasible, pharma-
cokinetic analyses should be undertaken to
obtain internal tissue dose metrics in the ani-
mals used in the studies. Next the mode of
action must be evaluated to determine the
relationship ofthe internal dose metric to the
effect and the proper extrapolation to humans.
These results are then extrapolated to humans
using both dosimetry and mode-of-action
information. Finally, the various possible
RfDs and RfCs must be compared with each
other, as well as any other relevant literature,
to determine ifany other factors should be
considered. Overall, RfDs and RfCs devel-
oped using the BMD methodwith pharmaco-
kinetic dosimetry and consideration ofmode
ofaction appear the most desirable because
they incorporate the greatest amount ofthe
scientific database into the regulatoryprocess.
One measure ofthe utilityofthis approach
is the consistency obtained for systemic effects
regardless ofwhether the exposure was oral or
by inhalation. The BMDs and toxicity values
derived from them (i.e., RfDs and RfCs) for
both liver andkidneyeffects areverysimilar by
these two routes. For example, the maximum
likelihood estimates for KTOX at the same
response level (BMR = 0.1) are very similar for
the oral and inhalation routes, 673 and 623
mg/L respectively, demonstrating good dose-
route extrapolation using the model. The
AUCTCA underlying the RfC and RfD for
liver effects are also similar, differing by a fac-
tor ofonly 2-3, though based upon studies
using different rodent strains, durations, and
routes ofexposure.
The analyses presented here have included
end points with widely varying databases.
Effects included those for which virtually no
data other than exposure and response were
available (i.e., eye malformations) and others
with varying amounts of data on mode of
action and pharmacokinetics that inform
extrapolations between exposure regimens
(e.g., less than chronic-to-chronic liver effects)
or between species (e.g., neurological effects).
Overall, the analyses suggest that an RfD in
the range of0.06-0.12 mg/kg/day based on
liver effects analyzed with AUCTCA as the
internal dose metric would also be protective
for the other end points evaluated. Similarly,
an RfC in the range of0.4-1.0 ppm based on
slow-wave sleep analyzed with CTCOH, as
the internal dose metric would be protective
for the other end points as well. Modifi-
cations ofthese numbers might arise from the
use ofalternative approaches for deriving the
BMDs or from different interpretations of
the mode-of-action and pharmacokinetic
considerations informing selection of
uncertaintyfactorvalues.
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